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Abstract
Vitamin D plays a major role in bone mineral homeostasis
by promoting the transport of calcium and phosphate to
ensure that the blood levels of these ions are sufficient
for the normal mineralization of type I collagen matrix in
the skeleton. In contrast to classic vitamin D-deficiency
rickets, a number of vitamin D-resistant rachitic syn-
dromes are caused by acquired and hereditary defects in
the metabolic activation of the vitamin to its hormonal
form, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), or in
the subsequent functions of the hormone in target cells.
The actions of 1,25(OH)2D3 are mediated by the nuclear
vitamin D receptor (VDR), a phosphoprotein which
binds the hormone with high affinity and regulates the
expression of genes via zinc finger-mediated DNA bind-
ing and protein\p=n-\proteininteractions. In hereditary hypo-
calcemic vitamin D-resistant rickets (HVDRR), natural
mutations in human VDR that confer patients with tissue
insensitivity to 1,25(OH)2D3 are particularly instructive in
revealing VDR structure/function relationships. These
mutations fall into three categories: (i) DNA binding/
nuclear localization, (ii) hormone binding and (iii)
heterodimerization with retinoid X receptors (RXRs).
That all three classes of VDR mutations generate the
HVDRR phenotype is consistent with a basic model of
the active receptor as a DNA-bound, 1,25(OH)2D3\x=req-\
liganded heterodimer of VDR and RXR. Vitamin D
responsive elements (VDREs) consisting of direct hexa-
nucleotide repeats with a spacer of three nucleotides have
been identified in the promoter regions of positively
controlled genes expressed in bone, such as osteocalcin,
osteopontin, \g=b\3-integrin and vitamin D 24-OHase. The
1,25(OH)2D3 ligand promotes VDR-RXR heterodimer-
ization and specific, high affinity VDRE binding, whereas
the ligand for RXR, 9-cis retinoic acid (9-cis RA), is
capable of suppressing 1,25(OH)2D3-stimulated transcrip-
tion by diverting RXR to form homodimers. However,
initial 1,25(OH)2D3 liganding of a VDR monomer
renders it competent not only to recruit RXR into a
heterodimer but also to conformationally silence the ability
of its RXR partner to bind 9-cis RA and dissociate
the heterodimer. Additional probing of protein\p=n-\protein
interactions has revealed that VDR also binds to basal
transcription factor IIB (TFIIB) and, in the presence of
1,25(OH)2D3, an RXR-VDR-TFIIB ternary complex
can be created in solution. Moreover, for transcriptional
activation by 1,25(OH)2D3, both VDR and RXR require
an intact short amphipathic \g=a\-helix,known as AF-2,
positioned at their extreme C-termini. Because the AF-2
domains participate neither in VDR-RXR heterodimer-
ization nor in TFIIB association, it is hypothesized that
they contact, in a ligand-dependent fashion, transcriptional
coactivators such as those of the steroid receptor coacti-
vator family, constituting yet a third protein\p=n-\protein
interaction for VDR. Therefore, in VDR-mediated
transcriptional activation, 1,25(OH)2D3 binding to VDR
alters the conformation of the ligand binding domain such
that it: (i) engages in strong heterodimerization with RXR
to facilitate VDRE binding, (ii) influences the RXR
ligand binding domain such that it is resistant to the
binding of 9-cis RA but active in recruiting coactivator to
its AF-2 and (iii) presents the AF-2 region in VDR for
coactivator association. The above events, including bridg-
ing by coactivators to the TATA binding protein and
associated factors, may position VDR such that it is able to
attract TFIIB and the balance of the RNA polymerase II
transcription machinery, culminating in repeated tran-
scriptional initiation of VDRE-containing, vitamin D
target genes. Such a model would explain the action of
1,25(OH)2D3 to elicit bone remodeling by stimulating
osteoblast and osteoclast precursor gene expression, while
concomitantly triggering the termination of its hormonal
signal by inducing the 24-OHase catabolizing enzyme.
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Introduction
Classic nutritional rickets is caused by the simultaneous
deprivation of sunlight exposure and dietary vitamin D.
As depicted in Fig. 1, the pathways comprising the
metabolic activation of the vitamin to its hormonal form
and subsequent functions in target tissues present a
number of additional steps where defects elicit vitamin
D-resistant rachitic syndromes. Two of these disorders
involve the inadequate bioactivation of 25-hydroxy¬
vitamin D3 (25(OH)D3) to 1,25-dihydroxyvitamin D3(l,25(OH)2D3) by the kidney as catalyzed by the
1-OHase enzyme (Fig. 1). Acquired chronic renal failure
results in renal rickets and secondary hyperparathyroidism(renal osteodystrophy) when the compromising of renal
mass reduces 1-OHase activity (Haussier oc McCain
1977). The etiology of pseudo-vitamin D-deficiency
rickets (PDDR) apparently involves a hereditary defect in
the gene coding for the 1-OHase enzyme (Labuda et al.
1992). Interestingly, the PDDR locus is resolvable from
that of the vitamin D receptor (VDR) but maps very close
to it on chromosome 12 in the 12ql3—14 region (Labuda
et al. 1992). Recently, a cDNA was cloned for the rat
1-OHase (St-Arnaud et al. 1996) and it is expected that
the human renal 1-OHase gene will soon be cloned and its
chromosomal location determined. The likelihood that
both the gene encoding the enzyme that generates the
l,25(OH)2D3 hormone and the cognate hormone receptor
gene lie in close proximity on chromosome 12 invites
speculation about the evolution of the vitamin D ligand-
receptor system.
The traditional actions of vitamin D, via its
l,25(OH)2D3 hormonal metabolite, are to effect calcium
and phosphate homeostasis to ensure the deposition of
bone mineral on type I collagen matrix (summarized in
Fig. 1). l,25(OH)2D3 stimulates intestinal calcium and
phosphate absorption, bone calcium and phosphate résorp¬
tion, and renal calcium and phosphate reabsorption, all
resulting in a sufficient CaP04 ion product to precipitate
hydroxyapatite. Failure to achieve normal bone mineral
accretion by these mechanisms leads to rachitic syndromes.
Recently, a breakthrough has occurred in our understand¬
ing of what was originally known as hypophosphatemic
vitamin D-resistant rickets, a familial disorder of renal
phosphate wasting more appropriately referred to as domi¬
nant X-linked hypophosphatemic (HYP) rickets (Fig. 1).
The gene defect responsible for HYP rickets has been fine
mapped in the Xp22T region, harboring a gene identified
as PEX, or phosphate regulating gene with homologies to
endopeptidases located on the X-chromosome (Francis
et al. 1995). One hypothesis is that PEX codes for an
endopeptidase that apparently correctly processes a peptide
precursor to yield a novel, as yet unidentified, phosphate
retaining hormone. The normal function of this hormone
may be to oppose the action of parathyroid hormone(PTH) and stimulate phosphate reabsorption by the renal
tubule by inducing the Na -phosphate cotransporter.
However, the existence of tumor-induced osteomalacia,
an acquired disorder that closely resembles the phosphate
wasting of HYP rickets and is characterized by low
circulating l,25(OH)2D3 (Parker et al. 1981), combined
with renal cross-transplantation (Nesbitt et al. 1992) and
parabiosis (Meyer et al. 1989) studies in normal and hyp
mice, indicates strongly that the HYP phenotype is caused
by excessive amounts of a phosphaturic hormone in the
circulation. This humoral peptide is distinct from PTH
and has been named phosphatonin (Cai et al. 199A, Econs
& Drezner 1994). Thus, instead of PEX mutations result¬
ing in insufficient generation of a novel phosphate-
retaining peptide, they may instead elicit the appearance of
abnormally high circulating levels of phosphatonin, with
the normal role of the PEX gene product postulated to be
the proteolytic inactivation of this phosphaturic principle.
Most germane to the vitamin D endocrine system is the
fact that serum l,25(OH)2D3 levels are inappropriately
low for the prevailing phosphate concentrations in HYP
rickets and patients can be cured with a therapeutic
combination of phosphate and l,25(OH)2D3 (Harrel et al.
1985). Because it is well known that hypophosphatemia
stimulates l,25(OH)2D3 production (Hughes et al. 1975),
the PEX/phosphatonin system might constitute yet
another regulatory loop in maintaining normal phosphate
homeostasis. One could hypothesize that under hypo¬
phosphatemic conditions, when l,25(OH)2D3 levels are
elevated, the sterol hormone not only increases intestinal
phosphate absorption (Fig. 1) and suppresses PTH syn¬
thesis (DeMay et al. 1992) to conserve phosphate, but also
induces the PEX gene product (Rowe et al. 1996) to
cleave phosphatonin and further promote renal phosphate
reclamation.
l,25(OH)2D3 is primarily recognized as a calcémie
hormone, perhaps due to the abundance of dietary phos¬
phate, or because calcium homeostasis is more vitamin
D-dependent than the regulation of extracellular phos¬
phate. Regardless of the mechanism, traditional vitamin
D-deficiency and clinically significant defects in the
vitamin D receptor lead invariably to hypocalcemia and
secondary hyperparathyroidism, with phosphate being
somewhat less affected. As illustrated in Fig. 1, target tissue
insensitivity to l,25(OH)2D3 is known as hereditary
hypocalcémie vitamin D-resistant rickets (HVDRR) and
is caused by defects in the gene on chromosome 12 coding
for the VDR. A review of the etiology of HVDRR and
the natural mutations in the VDR that confer tissue
insensitivity and clinical resistance to l,25(OH)2D3 is
particularly instructive in illuminating the physiologic
relevance of the l,25(OH)-,D3-VDR hormone-receptor
complex as well as structure/function relationships in the
receptor itself.
Natural mutations in the nuclear vitamin D
receptor
Clinically significant hereditary hypocalcémie vitamin
D-resistant rickets is an autosomal recessive disorder
resulting in a phenotype characterized by severe bowing of
the lower extremities, short stature and, often, alopecia
(Rut et al. 199A). The serum chemistry in HVDRR
includes frank hypocalcemia, secondary hyperpara¬
thyroidism, elevated alkaline phosphatase, variable hypo-
phosphatemia and markedly increased l,25(OH)2D3. The
symptoms of HVDRR, with the exception of alopecia,
mimic classic vitamin D-deficiency rickets, suggesting that
VDR not only mediates the bone mineral homeostatic
actions of vitamin D but may also participate in the
differentiation of hair follicles in utero. Recently, VDR
knockout mice have been created (Yoshizawa et al. 1996),
revealing apparently normal hétérozygotes but severely
affected homozygotes (VDR-/-), 90% ofwhich die within
8—10 weeks. Surviving mice lose their hair and possess low
bone mass, hypocalcemia, hypophosphatemia and 10-fold
elevated l,25(OH)2D3 coincident with extremely low
24,25(OH)2D3. All of these parameters in the VDR
knockout mouse mimic the phenotype of patients with
HVDRR, confirming that VDR normally mediates all of
the bone mineral regulating functions of vitamin D.
Interestingly, although natural point mutations in other
receptors related to VDR, such as thyroid hormone
receptor ß (TRß) (Collingwood et al. 1994), are charac¬
terized by dominant negative receptors that generate the
thyroid hormone resistant phenotype in the heterozygotic
context, no natural, dominant negative mutations have
yet been identified in HVDRR patients (Whitfield et al.
1996). Thus, all HVDRR cases studied to date are
homozygous for the particular VDR mutation.
Figure 2 illustrates a number ofpoint mutations in VDR
that have been detected in HVDRR patients (reviewed
in Rut et al. 199A, Haussler et al. 1995). Three of these
genetic alterations result in nonsense mutations that
introduce stop codons in VDR (K73stop, Q152sfo|> and
Y295stop), creating truncated VDRs that lack both
hormone- and DNA-binding (heterodimerization)
capacities and are associated with unstable mRNAs. More
revealing are the series of missense mutations (Fig. 2) that
can be classified according to three of the basic molecular
functions of VDR: (i) DNA binding/nuclear localization
by the N-terminal zinc finger region, (ii) l,25(OH)2D3
hormone binding by the C-terminal domain and (iii)
heterodimerization with retinoid X receptors (RXRs)
through subregions of the C-terminal domain. As depicted
schematically in Fig. 2 and discussed in detail later, VDR
is a ligand-dependent transcription factor that controls
gene expression by heterodimerizing with RXR and
associating specifically with vitamin D responsive elements(VDREs) in target genes. Since VDR is a member of the
steroid, retinoid, thyroid hormone receptor superfamily,
and belongs to the VDR/retinoic acid receptor(RAR)/TR subfamily of RXR heterodimerizing species(Haussler et al. 1991), it is reasonable to draw from data on
RAR and TR for comparison with VDR.
The greatest number of VDR natural mutations char¬
acterized to date are localized to the DNA binding, zinc
finger region (Fig. 2). The first two discovered, G33D and
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Figure 2 Natural mutations in the human vitamin D receptor leading to 1,25(OH)2D¡ hormone
resistance. See text for details and citations. N37, K91 and E92 are not sites of VDR natural mutations,
but are so designated because they ate heterodimerization contacts that lie within the DNA binding
domain (Hsieh et al. 1995, Rastinejad et al. 1995). The eight cysteine residues (C) that tetrahedrally
coordinate two zinc atoms in the finger sttucture are also denoted.
R73Q (Hughes et al. 1988), reside at the 'tips' of the
fingers and affect charge—charge interactions between
VDR and the phosphate backbone of DNA. When
viewed in toto, the zinc finger region mutations in
HVDRR (Fig. 2) have the following two general prop¬
erties: (i) they occur in residues conserved across the entire
nuclear receptor superfamily and (ii) most lie within
 -helices on the C-terminal side of the first and second
fingers which are intimately involved in DNA base
recognition and phosphate backbone contacts respectively(Rastinejad et al. 1995). These observations suggest that
many of the clinically significant mutations in VDR which
are still compatible with life may not greatly perturb the
fundamental structure of the DNA binding domain of
the receptor, but instead compromise its ability to recog¬
nize DNA with specificity and high affinity. Whether
HVDRR cases with mutations in zinc finger region
residues unique to VDR will be uncovered depends upon
the properties of such alterations, which could range from
innocuous to lethal.
Mutations located within the hormone binding domain
of VDR also elicit the HVDRR phenotype (Fig. 2),
including R274L (Kristjansson et al. 1993) and H305Q(Malloy et al 1995). Transcriptional activation by R274L
and H305G VDR is attenuated as a result of inefficient
l,25(OH)2D3 binding, ranging from severe in the case of
R274L to a modest increase in Kd for H305Q. In both
instances, transcriptional activation is restored when the
dose of l,25(OH)2D3 is raised to pharmacologie levels(10 m) in transfection experiments (Kristjansson et al.
1993, Malloy et al. 1995). Our laboratory has recently
characterized two novel VDR hormone binding domain
mutations in HVDRR patients, I314S and R391C, that
significantly affect the heterodimerization of VDR with
RXR (Whitfield et al. 1996). Both of these C-terminal
replacements (Fig. 2), however, do display some degree of
what may be a hormone binding deficit, a phenomenon
not observable in typical in vitro ligand binding kinetic
assays at 4 °C. Thus, only at 37 °C in intact cells do
R391C and I314S exhibit apparent slight and significant
impairment of l,25(OH)2D3 high affinity retention
respectively (Whitfield et al. 1996). Further, the two
mutations in question are situated in or adjacent to heptad
repeats (Fig. 2), hypothetical coiled-coil-like structures
that were originally proposed to participate in the
heterodimerization of VDR, RAR, and TR with RXR(Forman & Samuels 1990, Nakajima et al. 1994). Consist¬
ent with this concept, both R391C and I314S VDRs do
not bind RXR with normal affinity when assayed in vitro,
with the greatest impairment of heterodimerization occur¬
ring with R391C (affinity reduced by one order of
magnitude) (Whitfield et al. 1996). Additional evidence
supporting blunted RXR heterodimerization by these two
mutant VDRs is provided by transfection experiments in
which l,25(OH)2D3-stimulated transcription can be
restored to that of normal fibroblasts when fibroblasts
from patients harboring either the R391C or the I314S
mutation are cotransfected with exogenous RXR. Yet this
apparent RXR rescue of the mutated VDRs requires
approximately 10-fold elevated l,25(OH)2D3 doses com¬
pared with the response to hormone in normal fibroblasts(Whitfield et al. 1996). This latter observation reveals that
the hormone binding and heterodimerization functions
of VDR are not entirely separable, an aspect which is
also apparent from fundamental biochemical analysis of
the hormone dependency of VDR-RXR heterodimer
binding to VDREs as discussed in detail below.
Understanding the molecular properties of natural
VDR mutations in HVDRR allows us to comprehend
why the patients respond differentially to therapy with
massive doses of l,25(OH)2D3, or suitable analogs. For
example, cases with zinc finger region aberrations are
unresponsive to the hormone because DNA binding
is precluded by the absence of structural complemen¬
tarity between VDR and the VDRE, regardless of
the l,25(OH)2D3 liganding or heterodimerization of the
receptor in solution. Conversely, patients harboring
mutations in the hormone binding/heterodimerization
domain can be responsive to pharmacologie doses of
l,25(OH)2D3 or analogs, even though the hormone
already is increased in the circulation because of the
hypocalcemia caused by tissue insensitivity. For example,
patient I314S was essentially cured by excess vitamin D
metabolite, indicating that compensating for the hormone
binding deficit was able to override the milder hetero¬
dimerization defect and allow sufficient VDRE binding by
the VDR-RXR heterodimer. Conversely, patient R391C
responded only modestly to treatment with excess
l,25(OH)2D3 analog, presumably because the fundamen¬
tal heterodimerization defect could not be overcome and
therefore normal VDRE binding could not be achieved(Whitfield et al. 1996).
The final insights gained from the natural VDR
mutations summarized in Fig. 2 are structural in nature.
We have discussed previously that the zinc finger
mutations are confined to absolutely conserved residues.
In the crystal structure of the DNA binding domain
heterodimers ofRXRa and TRß (Rastinejad et al. 1995),
the lysine and arginine residues corresponding to K45 and
R50 in human VDR (hVDR) make direct base contacts
with DNA, while the arginines corresponding to R73 and
R80 in hVDR make direct DNA phosphate backbone
contacts. That mutations in these four residues are clini¬
cally important in the etiology of HVDRR argues for
structural congruity between the VDR finger region and
that of TR. Rastinejad et al. (1995) have extended this
assumption to include a modeling of RXR-TR vs RXR-
VDR bound to DNA which accommodates the fact that
TR binds as a heterodimer to a direct hexanucleotide
repeat spaced by four nucleotides (DR+4), while VDR
binds as a heterodimer to a similar set of half elements
spaced by three nucleotides (DR+3). In addition to
verifying the common protein-DNA interfaces, their
modeling predicts that hVDR residues N37 in the first
finger and K91/E92 C-terminal of the second finger (see
Fig. 2) engage in heterodimeric contacts with residues in
the second zinc finger ofRXR to form effectively a stable,
DNA-supported heterodimer. Indeed, recent site-directed
mutational studies (Hsieh et al. 1995) indicate that the
alteration of K91 and E92 in hVDR in fact grossly reduces
transactivation while moderately attenuating hetero¬
dimerization and DNA binding, thus confirming the
importance of K91 and E92. An additional surprising
finding was that the K91/E92 double mutant manifested
dominant negative characteristics (Hsieh et al. 1995),
distinguishing it from the natural HVDRR replacements
discussed above. Apparently, the K91/E92 mutant VDR
is able to bind DNA sufficiently through its native zinc
finger and strong heterodimerization function in the ligand
binding domain such that it can block binding by wild
type receptor, but is rendered inactive in stimulating
transcription because of a presumed conformational per¬
turbation initiated by unstable or improper alignment of
the heterodimer on the VDRE.
Based upon recently reported X-ray crystal structures of
the ligand binding domains of ligand-occupied hRARy(Renaud et al. 1995), agonist-occupied rat TRa, (Wagner
et al. 1995) and unoccupied, but dimeric hRXRa(Bourguet et al. 1995), it is also possible to incorporate
the HVDRR mutations in the hormone binding domain
(Fig. 2) into a hypothetical structural context. Figure 3
constitutes a schematic compilation of the existing crystal-
lographic data and compares them with natural and
artificially generated mutations in hVDR. At the top of
Fig. 3, the residue numbers for VDR in the ligand binding
domain appear in relation to the older heptad repeat
nomenclature (heptads 1—9, dotted boxes). At least some of
these heptads, particularly heptads 4 and 9, are thought to
facilitate heterodimerization (Nakajima et al. 1994). The
El region is a highly conserved area that supports
heterodimerization (Whitfield et al. 1995è). The helices
depicted schematically in Fig. 3 (open boxes) are those
determined for hRARy; this general pattern of  -helices
and ß-strands (solid boxes) appears to be well conserved
across the TR, RAR and RXR members of the subfamily
crystallized thus far (Bourguet et al. 1995, Renaud et al.
1995, Wagner et al. 1995). Although the heterodimeriz¬
ation domains have yet to be elucidated by structural
analysis, the homodimerization domain of RXR is com¬
prised of helices 7, 9 and 10 (Fig. 3 and Bourguet et al.
1995). Flanking the dimerization region are clusters of
ligand binding contacts, shown for RAR and TR in
Fig. 3, which paint a picture of hormone binding involv¬
ing helices 3, 5, 11 and 12 plus portions of helices 6 and 7
along with their intervening loop, as well as the loop
between ß-strands 1 and 2. As summarized in Fig. 3 and
Figure 3 Hormone binding (R274L and H305Q) and heterodimerization (I314S and R391C) natural
mutations in VDR that confer the HVDRR phenotype are positioned in the context of retinoid and
thyroid hormone receptor subfamily ligand binding domain structures. See text for details and citations.
discussed by Whitfield et al. (1995a, 1996), a number of
artificially generated mutants in hVDR support the con¬
cept that the dimerization and honnone binding regions in
VDR are well aligned with those in RXR, RAR and TR.
Of even greater interest and relevance to the present
monograph, the four clinically important hVDR mutants
under consideration correspond to pertinent locations in
the known structures of the retinoid and thyroid hormone
receptor ligand binding domains. We postulate that this
general structural organization represents that of the VDR
ligand binding domain. As shown in Fig. 3, the pure
hormone binding mutant hVDRs, namely R274L and
H305Q, are located precisely within ligand clusters in
helix 5 and in the loop between helix 6 and 7 respectively.
I314S, which endows hVDR with combined defects in
hormone retention and heterodimerization, lies within
helix 7 at a presumed interface of ligand binding and
dimerization activities of the receptor (Fig. 3). Finally,
R391C is positioned well within the helix 10 dimerization
surface, but not far removed from C-terminal ligand
binding contacts that are likely influenced by replacement
of this amino acid in hVDR. Thus, at least within the
context of the assumed structural organization of VDR
derived from that of other subfamily members, the I314S
and R391C mutations are situated precisely where they
would be predicted to lie, given the biological properties
of the mutant receptors and the phenotype of the patients.
These results not only have profound implications con¬
cerning the putative structure of VDR in relation to its
closest relatives, but prove unequivocally that the calcémie
actions of l,25(OH)2D3 are mediated by the vitamin D
receptor, existing as a l,25(OH)2D3-liganded heterodimer
with RXR that is bound to DNA.
Physiology and cellular actions of l,25(OH)2D3
In order to delineate the physiologic roles for the vitamin
D hormone, it is appropriate first to place the VDR
mediator into the context of vitamin D metabolism and
cellular actions. Figure 4 summarizes the integration of
vitamin D metabolism and cellular actions introduced in
Fig. 1, with physiologic regulatory events now super¬
imposed on the metabolic pathway and the inclusion of an
expanded list of physiologic actions for the 1,25(  )2 4
hormone. The conversion of vitamin D3 to 25(OH)D3 by
the liver is a constitutive metabolic step, followed by the
1-hydroxylation of 25(OH)D3 to l,25(OH)2D3, a reaction
under exquisite control (Haussler & McCain 1977). When
blood calcium is low, activation of this latter step occurs,
either as a result of the hypocalcémie state per se, or in
response to elevated PTH, each of which serves indepen¬
dently to enhance renal 1-OHase activity. Low phosphate
is also capable of separately upregulating the 1-OHase
enzyme. To limit activation, the hormonal product,
l,25(OH)2D3, effects an ultra-short feedback loop to
suppress its own biosynthesis in the kidney and also
represses PTH synthesis to remove the peptide hormone
stimulus of the 1-OHase via a longer feedback loop(Fig. 4). However, the dominant negative feedback
controls of 1-OHase activity appear to result from the
concerted actions of l,25(OH)2D3 to stimulate bone
mineral résorption and to promote intestinal calcium and
phosphate absorption, which together elicit an increase
in blood calcium and phosphate levels, each of which
down-regulates the 1-OHase.
The process by which l,25(OH)2D3 causes bone
remodeling is complex, involving stimulation of osteoclast
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Figure 4 Vitamin D metabolism and cellulat actions, mediated by the VDR-RXR heterodimer binding to
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differentiation and osteoblastic production of osteopontin,
both of which activate résorption in part through the
recognition of bone matrix osteopontin by osteoclast sur¬
face avß3-integrin. The résorption effect is supported by
l,25(OH)2D3-elicited suppression of bone formation via
the induction of osteocalcin and the repression of type I
collagen. This latter insight that the normal function of
osteocalcin is to curtail bone matrix formation arises from
the creation of osteocalcin knockout mice (Ducy et al.
1996). In addition to stimulating the transcription of
bone-related genes such as osteopontin and osteocalcin,
the l,25(OH)2D3 hormone also induces its own eatab¬
olism in kidney as well as other target tissues like bone by
enhancing the expression of the vitamin D-24-OHase
enzyme. 24-Hydroxylation of l,25(OH)2D3 is the first
step in deactivating the hormone, which is eventually
metabolized by side chain cleavage to calcitróle acid(Haussler 1986). Thus, the synthesis of l,25(OH),D3 is
not only governed by feedback mechanisms that sense
l,25(OH)2D3, calcium, PTH and phosphate concen¬
trations, but the hormone induces the termination of its
own signal in target tissues, qualifying l,25(OH)2D3 as a
bona fide hormone by any definition.
As introduced in the section on HVDRR, mediation
of the cellular functions of l,25(OH)2D3 requires that
VDR bind the hormonal ligand specifically and with
high affinity (Fig. 4). Upon such binding, VDR
becomes hyperphosphorylated (Jurutka et al. 1993,
Haussler et al. 1994) and recruits RXR into a hetero¬
dimeric complex that binds strongly to DNA (Fig. 4).
The l,25(OH)2D3-hganded RXR-VDR heterocomplex
selectively recognizes VDREs in the promoter regions of
positively controlled genes such as osteocalcin (MacDonald
et al. 1991), osteopontin (Noda et al. 1990), vitamin
D-24-OHase (Ohyama et al. 199A) and ß3-integrin (Cao
et al. 1993). Negative VDREs (Haussler et al. 1995) exist
in the 5'-regions of the genes for type I collagen (Pavlin
et al. 199A), bone sialoprotein (Li & Sodek 1993), PTH(DeMay et al. 1992) and PTH-related peptide (Falzon
1996, Kremer et al. 1996). The mechanisms whereby
VDR accomplishes positive and negative control of DNA
transcription after VDRE association are not well under¬
stood, although substantial progress has been made in
comprehending the stimulation of transcription as detailed
in later sections of this article. Moreover, as summarized in
Fig. 5, a number of VDREs have been definitively
characterized. The prototypical VDBJS is found in the
osteocalcin gene, consisting ofan imperfect direct repeat of
hexanucleotide estrogen responsive element (ERE)-like,
half-sites with a spacer of three nucleotides (DR+3).
Classic EREs possess a central GT core at positions 3 and
4 of the hexanucleotide, but this feature is only partially
conserved in the six natural positive VDREs listed in
Fig. 5. There is, however, absolute conservation of the A
in position 6 of the 5' half-element and of the G at position
2 of the 3' half-element. A preliminary working consensus
for the positive VDRE can be derived from these natural
VDREs (see boxed sequence in Fig. 5). This generaliz¬
ation is supported, in part, by PCR experiments that
were designed to select, from random oligonucleotides,
the highest affinity DNA ligand for the RXR-VDR
heterodimer (Nishikawa et al. 1994, Colnot et al. 1995).
Rat Osteocalcin
Human Osteocalcin
Mouse Osteopontin
Rat 24-OHase-Distal
Rat 24-OHase-Proximal
Avian ß3 Integrin
GGGTGA
GGGTGA
GGTTCA
GGTTCA
AGGTGA
GAGGCA
G
ACG
CGA
GCG
GTG
GAA
AGGACA
GGGGCA
GGTTCA
GGTGCG
AGGGCG
GGGAGA
Positive VDRE Consensus GGGTCA GNG GGGGCA
Consensus by
Random Selection  GGTCA NNG
G Ica
Figure 5 Natural vitamin D responsive elements (DR+3s) in genes positively tegulated by
l,25(OH)2D3. The consensus VDREs are based on either sequence comparisons (boxed) or
a selection of random sequences (at bottom).
The random selection process yields an identical VDRE 5'
half-element of GGGTCA (Fig. 5, bottom), which is also
a preferred RXR target when RXR homodimers bind to
DNA (Yang et al. 1995). This observation is in concert
with the conclusion (Jin & Pike 1996) that, with respect to
association ofRXR-VDR with VDREs, RXR lies on the
5' half-element whereas VDR is situated on the 3'
half-element. Examination of both consensus sequences
suggests that the G at position 3 of the spacer is important
in VDR binding, a deduction consistent with the finding(MacDonald et al. 1991) that this base is partially protected
by RXR-VDR in methylation interference assays. How¬
ever, interesting differences arise when one compares the
most frequently encountered 3' half-element bases in
natural VDREs, namely the GGGGCA composite which
actually occurs in human osteocalcin, with the GGTTCA
random consensus selection for the 3' half-element
(Fig. 5). Clearly, GGTTCA represents a potent VDR
binding site, a supposition that is bolstered by the fact
that osteopontin, which possesses a perfect DR+3 of
GGTTCA, is the highest affinity VDRE we have tested(data not shown). Intriguingly, Ts at positions 3 and 4 in
the 3' VDR half-site occur infrequently in the balance of
natural VDREs (Fig. 5). The paucity of Ts in the 3'
half-element could be related to a need for varying
potency of VDREs in regulated genes, or may even
provide for a repertoire of different VDR conformations
that could be induced by contact with distinct 3' half-site
core sequences. This postulated range of VDR conforma¬
tions might endow the receptor with the ability to recruit
a variety of different coactivators and corepressors, or even
to favor the binding of one vitamin D metabolite ligand
over another. Irrespective of the above considerations, it is
evident that the primary VDRE is a DR+3 recognition
site in DNA that directs the VDR to the promoter region
of l,25(OH)2D3 regulated genes, ultimately altering the
functions of target cells as a result of transcriptional control
of gene expression.
Significance of lipophilic ligands in the association
of RXR-VDR with DNA
Dimeric complexes are a feature commonly employed in
the regulation of eukaryotic transcriptional systems. This
process of protein dimerization often will generate novel
heterodimeric complexes which display highly cooperative
binding to DNA as well as an altered target sequence
specificity (Glass 1994). Among the classical steroid hor¬
mone receptors, dimerization results in the formation of
symmetrical homodimeric protein complexes on palindro-
mic DNA half sites. Dimerization has been shown to be
mediated in part by residues within the DNA binding
domain of the receptor (Luisi et al. 1991) and is enhanced
by residues within the ligand binding domain (Falwell
et al. 1990). The other subfamily of nuclear hormone
receptors, including VDR, TR and RAR, apparently
binds with highest affinity to direct repeat elements either
as homodimers or, more commonly, as heterodimers with
RXR (Kliewer et al. 1992). In both subgroups of nuclear
receptors, protein-protein interactions serve to align the
DNA binding domains so that they are optimally pos¬
itioned to bind to their specific DNA target sequences(Kurokawa et al. 1993, Perlmann et al. 1993, Rastinejad
et al. 1995). The ligand binding region of these receptors
is multifunctional, in that this domain not only binds
the cognate ligand, but also it possesses a dimerization
surface as well as the ligand-dependent transactivation
function, AF-2 (Gronemeyer 1991, Chambón 1994). The
dimerization surface consists of packed helices which are
stabilized by hydrophobic heptad repeats interspersed
throughout the structure. Ligand apparently can influence
different functional components, including the dimeriz¬
ation interface, and the activating AF-2 domain (Renaud
et al. 1995, Wagner et al. 1995). Therefore, a likely role for
ligand is to regulate the association and dissociation of
dimeric protein complexes and hence regulate specific
binding to DNA target sequences.
In this regard the following three questions remain
regarding l,25(OH)2D3-mediated control of positively
regulated genes: (i) does VDR bind as a homodimer(Freedman et al. 1994, Nishikawa et al. 1994) as well as a
heterodimer to DR+3 VDREs? (ii) What is the effect of
the l,25(OH)2D3 ligand on VDR or VDR-RXR binding
to VDREs? (iii) What role does 9-cis retinoic acid, the
RXR ligand, play m RXR-VDR binding to VDREs and
enhanced transcription of l,25(OH)2D3-responsive genes?
It is generally accepted that TR forms homodimers as
well as heterodimers with RXR on thyroid hormone
responsive elements (TREs), although recent data suggest
that the TR homodimer, when unoccupied by thyroid
hormone, operates as a repressor of transcription (Chin &
Yen 1996, Schulman et al. 1996). Thyroid hormone is
proposed to dissociate TR homodimers to facilitate TR-
RXR heterodimerization on the TRE and stimulate
transcription. In contrast, RAR does not appear to be
capable of forming homodimers on DR+5 retinoic acid
responsive elements (RAREs) (Perlmann et al. 1996),
instead cooperating exclusively with RXR in RARE
association and vitamin A metabolite-responsive transcrip¬
tion. When present in excess in gel mobility shift DNA
binding assays in vitro, both TR and RAR display RXR
heterodimeric association with their respective hormone
responsive elements (HREs) in the absence of added
lipophilic ligand. These in vitro studies are consistent with
immunocytochemical data indicating that, unlike classic
steroid honnone receptors that reside in the cytoplasm
complexed with Hsp-90 and other proteins in their
unoccupied state, unliganded TR, RAR and VDR(Clemens et al. 1988) exist in the nucleus in general
association with DNA. These findings have led to the
dogma that ligand is not required for TR, RAR and VDR
to associate with target HREs. Indeed, we have observed
that addition of 260 ng baculovirus-expressed hVDR to a
gel shift reaction generates weak homodimeric VDR as
well as strong VDR-RXR-heterodimeric binding to a rat
osteocalcin VDRE probe, both of which are independent
of the presence of l,25(OH)2D3 (Nakajima et al. 1994).
However, in vivo footprinting experiments (Blanco et al.
1996, Chen et al. 1996) have led to the conclusion that, at
least in the case of RAR-RXR heterodimers, RAR
ligands are required for RARE binding. We, therefore,
sought to devise an in vitro gel shift assay that would more
accurately reflect the in vivo situation, primarily consisting
of the use of physiologic salt (0-15 m KCl) concentrations
and limited amounts of partially purified, baculovirus-
expressed VDR and RXRs (Thompson et al. 1997).
Utilizing this assay, we have addressed the three questions
regarding VDR/RXR listed above, namely heterodimer
versus homodimer, the potential role of l,25(OH)2D3 and
the effect of 9-cis retinoic acid (9-cis RA).
When 20 ng VDR (~ 10 nM) or 20 ng VDR plus 20 ng
RXR are incubated with either the rat osteocalcin or
mouse osteopontin VDREs (see Fig. 5), no DNA-bound
homodimeric VDR species is apparent, but a VDRE
complexed VDR-RXR heterodimer occurs that is strik¬
ingly dependent upon the presence of the l,25(OH)2D3
ligand (Thompson et al. 1997). Thus, at receptor levels
approaching that in a typical target cell, a VDR ligand-
dependent heterodimer with RXR is the preferred
VDRE binding species. Only when VDR or VDR plus
RXR levels are raised to 100 ng of each receptor with the
mouse osteopontin VDRE (Thompson et al. 1997), or
260 ng with the weaker rat osteocalcin VDRE (Nakajima
et al. 1994), can faint homodimers of VDR bound to the
probe be visualized. In addition, at these greater amounts
of receptors, neither the VDR homodimer nor the VDR-
RXR heterocomplexes are modulated significantly by
inclusion of l,25(OH)2D3 in the incubation (Thompson
et al. 1997). We, therefore, conclude that higher receptor
levels in vitro generate artifactual VDR homodimers as well
as attenuate the normal physiological ligand dependence of
VDR-RXR binding to the VDRE. To explain seemingly
ligand-independent VDR-RXR association with the
VDRE, we postulate the existence of a subpopulation
of VDR that is unstably activated in the absence of
l,25(OH)2D3 (Schulman et al. 1996) and therefore capable
of heterodimerization to generate a positive gel mobility
shift under conditions of vast receptor excess. In contrast,
our physiologically relevant gel shift assay at <10nM
receptor levels and 0-15 m KCl reflects the presumed
in vivo events of ligand triggered heterodimerization(Blanco et al. 1996, Chen et al. 1996), and extends earlier
in vitro data showing that l,25(OH)2D3 enhances VDR-
RXR complex formation (Sone et al. 1991, MacDonald
et al. 1993, Ohyama et al. 1994).
Next, we tested the effect of 9-cis RA in this gel shift
assay. A spectrum of data exists on the role of 9-cis RA in
l,25(OH)2D3-stimulated transcription, including demon¬
stration of synergistic action with l,25(OH)2D3 (Carlberg
et al. 1993, Schrader et al. 1994, Kato et al. 1995, Sasaki
et al. 1995), negligible action (Ferrara et al. 1994), or an
inhibitory effect (MacDonald et al. 1993, Jin & Pike 1994,
Lemon & Freedman 1996). These marked differences
likely result from varying transfection and ligand addition
protocols, as well as cell and species specificity. Employing
the physiological gel shift procedure with biochemically
defined components, we obtained clear evidence that 9-cis
RA is a potent inhibitor of l,25(OH)2D3-enhanced,
VDR-RXR binding to VDREs such as osteocalcin,
with dramatic attenuation by the retinoid occurring at
Figure 6 Model of two different allosteric pathways for VDR-RXR-1,25(OH)2D3 binding to DNA.
concentrations as low as 10 m (Thompson et al. 1997).
Previous gel shift data had also hinted at 9-cis RA
inhibition (MacDonald et al. 1993, Cheskis & Freedman
1994), even though higher concentrations of 9-cis RA
were utilized in these earlier studies. One somewhat
puzzling finding, however, was that the suppressive
effect of 9-cis RA seemed more pronounced in vitro than
in transfected cells, where retinoid inhibition of
l,25(OH)2D3-stimulated transcription is significant, but
50% or less in magnitude (MacDonald et al. 1993). This
suggested that multiple pathways may exist for the
assembly of the RXR-VDR heterocomplex in vivo. To
probe for distinct routes of assembly, we varied the order
of addition ofVDR, RXR, l,25(OH)2D3 and 9-cis RA in
the gel shift assay for VDRE binding (Thompson et al.
1997). The results showed that 9-cis RA is a potent
inhibitor of VDR-RXR heterodimerization on the
VDRE in all situations except when VDR alone is
preincubated with l,25(OH)2D3 followed by addition of
RXR (Thompson et al. 1997). To explain these data, we
have developed the model depicted in Fig. 6, which
hypothesizes two alternative allosteric pathways for the
interaction ofVDR-RXR with the VDRE. In pathway A(Fig. 6), l,25(OH)2D3 occupies monomeric VDR, alter¬
ing the conformation of the ligand binding domain such
that it recruits RXR for heterodimeric binding to DNA
and subsequent VDRE recognition. Importantly, we pos¬
tulate that previously occupied VDR conformationally
influences RXR in the resulting heterodimer such that it
is incapable of being liganded by 9-cis RA (pathway A,
Fig. 6). This action to abolish RXR ligand responsiveness
both silences the ability of 9-cis RA spuriously to trigger
vitamin D hormone signal transduction, and prevents 9-cis
RA from dissociating the RXR-VDR complex in order
to divert RXR for retinoid signal transduction. On the
other hand, as illustrated in pathway  (Fig. 6), we propose
that RXR exists in a different, 9-cis RA-receptive,
allosteric state in most other circumstances, such as when
present as a monomer, in an apoheterodimer with VDR,
or even when the apoheterodimer of RXR and VDR is
subsequently liganded with l,25(OH)2D3. This latter
species of RXR-VDR-l,25(OH)2D3 (pathway B) is
hypothesized to be fully competent in VDRE recognition,
but the 9-cis RA binding function of the RXR partner has
not been conformationally repressed, rendering this form
sensitive to dissociation by 9-cis RA, which would then
favor the formation of retinoid-occupied RXR homo¬
dimers. Therefore, unless VDR monomers are first occu¬
pied by l,25(OH)2D3 (pathway A), 9-cis RA can operate
to divert or dissociate RXR and direct it to form RXR
homodimers (pathway B). It is tempting to speculate that
the l,25(OH),D3-liganded heterodimer in pathway A
is more potent in transcriptional stimulation than the
analogous species in pathway B, perhaps because the AF-2
function of the RXR partner is allosterically activated only
in the former instance. The l,25(OH)2D3-occupied
VDR-RXR in pathway  has the advantage of flexible
regulation because it is effectively a two-ligand switch. It
likely occurs in vivo because, as stated above, the fact that
9-cis RA blunting of l,25(OH)2D3 responsiveness is
significant but incomplete suggests that at least two
populations of RXR-VDR heterodimers exist. Finally,
when our model (Fig. 6) is compared with those for
RXR-RAR and RXR-TR (Forman et al. 1995), it is
evident that VDR is closer in mechanism of action to the
TR, where 9-cis RA inhibits TR signal transduction by
diversion of BJÍR (Lehmann et al. 1993). Also analogous
is the fact that thyroid hormone occupation of the TR
partner abolishes 9-cis RA binding to the RXR counter¬
part (Forman et al. 1995). Finally, the action of RXR-
PJ\R heterodimers seems to be fundamentally different
from that of RXR-VDR in that RAR liganding by a
retinoid facilitates RXR occupation by its retinoid ligand,
resulting in cooperative stimulation of gene transcription
by the repertoire of vitamin A metabolites.
VDR protein-protein interactions that effect
gene transcription
Although we now have at least a rudimentary understand¬
ing of ligand-induced VDR binding to a VDRE, the next
logical question is how does VDR regulate the machinery
for gene transcription? In the basal state ofDNA transcrip¬
tion, the TATA-box binding protein (TBP) and its
associated factors (TAFs) are bound to the TATA box at
approximately position
—
20 in the 5' region of controlled
genes, but the frequency of transcriptional initiations is
very low because the RNA polymerase II-basal transcrip¬
tion factor IIB (TFIIB) enzyme complex is not stably
associated with TBP-TAFs. The recruitment of the
TFIIB-RNA polymerase II complex appears to be the rate
limiting step in preinitiation complex formation, and is
stimulated dramatically when a transacting factor or factors
bind to upstream enhancers. In a process involving DNA
looping, transactivators are thought to attract TFIIB and
also interact with TAFs, forming a stable preinitiation
complex that executes repeated rounds of productive
transcription. Recent data indicate that the activation
function in the hormone binding domain of the estrogen
receptor, AF-2, associates specifically with a TAF known
as TAFn30 (Jacq et al. 1994) and that the estrogen receptor
(ER) binds to TFIIB in vitro (lng et al. 1992). In
collaboration with Ozato and associates and Tsai and
O'Malley, we have observed that hVDR also specifically
associates with hTFIIB (Blanco et al. 1995). In this work,
Blanco et al. (1995) showed that VDR binds to a
TFIIB-glutathione S transferase fusion protein linked to
glutathione-laden beads. Additionally, it was observed that
both TRa and RARa interact with hTFIIB (Blanco et al.
1995), but that RXR does so only very weakly (P W
Jurutka, L S Remus and M R Haussler, unpublished
results). This last result suggests that, while the ligand
binding partners in the VDR/TR/RAR subfamily pro¬
vide a hard-wired connection to the assembly and en¬
hancement of the transcription machinery, the RXR
partner is not primarily engaged in TFIIB contact.
Independent data obtained by MacDonald et al. (1995)
using the powerful yeast two-hybrid system to detect
protein-protein interactions also revealed that hVDR
binds efficiently to TFIIB. Moreover, MacDonald et al.(1995) further exploited the yeast two-hybrid system to
prove that, while hVDR and RXR interact, no homo-
dimeric association occurs for hVDR alone, providing
further evidence against the existence of physiologically
significant VDR homodimers. Utilizing fusion protein
technology, they also showed that VDR interacts directly
with RXR to form a heterodimer in solution in the
absence of DNA and, further, that this process was
enhanced 8-fold by the presence of l,25(OH)2D3 hor¬
mone (MacDonald et al. 1995). Because hVDR-TFIIB
association is not dependent upon the l,25(OH)2D, ligand(Blanco et al. 1995, MacDonald et al. 1995), the role of
l,25(OH)2D3 can now be further resolved to an early
participation in conforming VDR such that it attracts
RXR followed by the targeting of the resulting
RXR-VDR heterodimer to VDREs (see Fig. 6).
Interestingly, the presence of BJCR further facilitates
VDR-TFIIB association, especially in the presence of
l,25(OH)2D3 (PW Jurutka, LS Remus and MR
Haussler, unpublished results). In fact, because of its
capacity to enhance VDR-RXR heterodimerization, the
l,25(OH)2D3 ligand is capable of generating high levels of
an RXR-VDR-TFIIB ternary complex in solution, sig¬
nificantly in excess ofthat occurring with either RXR and
TFIIB or even with VDR and TFIIB (P W Jurutka, L S
Remus and M R Haussler, unpublished results). These
data not only reaffirm the interaction ofVDR with TFIIB,
but also they imply that the l,25(OH)2D3-liganded
VDR-RXR complex is the most efficient binder of
TFIIB. This latter effect may be the result of positive
conformational influences of RXR on liganded VDR,
since VDR is the primary attachment moiety for TFIIB.
Because VDR-TFIIB interactions have been detected
either in vitro or in the yeast system where certain
mammalian cell restrictions may be relaxed, it was import¬
ant to confirm the relevance of VDR-TFIIB association in
mammalian cells. Blanco et al. (1995) have reported
functional studies which, for the first time, show the
interaction ofTFIIB with a member of the steroid receptor
superfamily in ligand-dependent activation of transcription
in intact cells. In pluripotent PI9 mouse embryonal
carcinoma cells, transfection of hVDR or hTFIIB alone
produced no better than a 2-fold induction of VDRE-
luciferase reporter expression by l,25(OH)2D3. However,
when transfected together, hVDR and hTFIIB mediated
a synergistic transcriptional response of approximately
30-fold when l,25(OH)2D3 was added, an effect which
was absolutely dependent on the presence of the VDRE
in the luciferase construct. It should be noted that the
VDR-TFIIB positive cooperation appears to be cell-
specific because similar experiments in contact-inhibited
NIH/3T3 Swiss mouse embryo cells resulted in
402 423
hVDR RCLSFQPECSMKLTPLVLJÊ)VFG
rTRO. «-helix 11 \ \ «-helix 12 \
hTRa LHMKVECPTEL-FPPLFlIËVfE
hTRß LHMKVECPTEL-FPPLFLIBJVFE
a-helix 11 |- a-helix 12hRARy
hRAROC RVITLKMEIPGSMPPLI J|E|ML·EhRARß RVITLKMEIPGPMPPLIQEMLE
tlRARy RAITLKMEIPGPMPPLIPjÍmLE
hRXROL \ «-helix iff -j
hRXROC FFFKLIGDTP-
hRXRß FFFKLIGDTP-
llRXRy FFFKLIGDTP-
a-helix 12
-IDTFLMBlLE
-IDTFLMEMLE
 IDSFDMyMLE
hER --YSMKCKNWPLYDLLLEMLD
hAR DLLIKSHMVSVDFPEMMAEIIS
hGR QTFLD-KTMSIEFPEMLAEIIT
hPR NTFIQSRALSVEFPEMMSiVIA
AF-2 Consensus:
 
  [ |  
Figure 7 The extreme C-terminal amino acid sequence compared
across the nuclear receptor superfamily: VDR appears to share the
ligand-dependent transcription activation function (AF-2). AR,
androgen receptor; CR, glucocorticoid receptor; PR, progesterone
receptor.
squelching of transcription by TFIIB. Therefore, in more
differentiated cells, perhaps including osteoblasts or fibro¬
blasts, accessory coactivators may be present to modulate
TFIIB or bridge between VDR and TFIIB.
In summary, VDR and TFIIB are hypothesized to exist
in a multi-subunit transcription complex which also con¬
tains TAFs and/or coactivators that may be promoter- or
tissue-specific. Further characterization of this complex
will require the discovery of cell type and promoter-
specific components via transfection and biochemical
interaction studies. Ultimately, an in vitro transcription
system must be devised which utilizes defined components
to replicate faithfully l,25(OH)2D3-stimulated gene
expression.
One subdomain of VDR that likely interacts with
coactivators and/or basal transcription factors is the
extreme C-terminus. We have previously shown that
 403 hVDR, a truncated receptor that lacks the
C-terminal 25 amino acids, binds l,25(OH),D3 ligand
with reasonable affinity and heterodimerizes normally with
RXR, but is devoid of transcriptional activity (Nakajima
et al. 1994). These data suggest that VDR contains a
transcriptional activation domain near its C-terminus.
Indeed, as illustrated in Fig. 7, the region of VDR from
residues 416 to 422 possesses a high degree of similarity to
the analogous sequences in the entire nuclear receptor
superfamily. One hallmark of this conserved sequence is
the glutamic acid residue at position 420 of hVDR (Fig. 7)
included in a consensus of
      
(where cp=a hydro-
phobic amino acid) for this domain (Renaud et al. 1995,
Wagner et al. 1995). Allowing for conservative replace¬
ments, it seems virtually certain that hVDR forms an
amphipathic helix (corresponding to helix 12 in the other
receptors) surrounding glutamic acid-420 that is analogous
to the ligand-dependent activation function (AF-2) char¬
acterized for TR (Barettino et al. 199A), RAR (Renaud
et al. 1995), RXR (Leng et al. 1995) and ER (Danielian
et al. 1992). Although this AF-2 domain is capable of
autonomously activating transcription (Leng et al. 1995),
that such activity is modest may be because of the fact that
the AF-2 region is proposed to operate in a ligand-
dependent fashion, involving a structural rearrangement to
reposition the AF-2 for both intramolecular and inter-
molecular protein—protein interactions. Specifically, based
upon the crystal structure of unoccupied RXR (Bourguet
et al. 1995) and liganded RAR (Renaud et al. 1995) and
TR (Wagner et al. 1995), helix 12/AF-2 appears to
protrude outward from the more globular ensemble of
helices 1—11 in the absence of ligand, such that it is unable
to interact efficiently with coactivator/transcription factor.
Upon liganding, a conformational signal is then transmit¬
ted to helix 12 that causes it to fold back on helix 11 and
attach to the face of the globular ligand binding domain.
The pivoting of helix 12 seemingly accomplishes two feats
that mediate ligand-activated transcription by the receptor:(i) closing of a 'door' on the channel through which the
lipophilic ligand enters the internal binding pocket of the
receptor, and (ii) locking helix 12 into a stable confor¬
mation that facilitates its interaction with coactivator/
transcription factor. Ligand binding contacts on or near
helix 12 (see Fig. 3) probably are significant in maintaining
this active positioning of helix 12, essentially trapping
ligand in the binding pocket to effect more sustained
transactivation events.
In order to evaluate the relevance of the above proposed
mechanism for VDR action, we (Jurutka et al. 1997) have
altered E-420 and L-417 (see Fig. 7) individually to
alanine residues, which preserves the putative  -helical
character of this region. The altered VDRs bind ligand
near-normally, with only a mild increase (about 3-fold) in
the Kd for the E420A receptor. Both E420A and L417A
hVDRs also heterodimerize efficiently with RXR and
associate with VDREs similarly to wild-type hVDR, yet
their capacity for l,25(OH)2D3-stimulated transcription is
abolished, even at high doses of ligand (Jurutka et al. 1997).
These point mutations, therefore, identify a C-terminal
AF-2 in VDR which corresponds to similar activation
domains in other nuclear receptor superfamily members.
Because VDR interacts with TFIIB, one of the first
questions we asked was whether the VDR AF-2 consti¬
tutes a contact site for this basal transcription factor.
Although some very preliminary evidence existed for an
association between TFIIB and the C-terminus of hVDR
(MacDonald et al. 1995), we observed that neither the
E420A nor the L417A mutant VDRs are impaired in their
interaction with TFIIB as probed with glutathione-S-
transferase—TFIIB fusion protein binding technology(Jurutka et al. 1997). Thus, the domain(s) of VDR that
interfaces with TFIIB apparently lies elsewhere in the
receptor, possibly in the N-terminal portion of the
ligand-binding region (Blanco et al. 1995), in the hinge(MacDonald et al. 1995), or in the vicinity of the
DNA-binding zinc fingers.
The present experiments with VDR are in concert with
recent insight into the function of AF-2 in other nuclear
receptors, which is to recruit coactivators of the type of
steroid receptor coactivator-1 (SRC-1) (Oñate et al. 1995).
A number of candidate coactivators have been isolated in
addition to SRC-1 (Halachmi et al. 199A, Baniahmad et al.
1995, CavaiUes et at. 1995, Lee et al. 1995, Hong et al.
1996) and, in several cases, interaction with nuclear
receptors requires intact AF-2 core regions (Baniahmad
et al. 1995, CavaiUes et al. 1995). Moreover, AF-2
mutations act as dominant negative receptors, for example
in the case of hRARy (Renaud et al. 1995). Indeed, we
have observed that VDR AF-2 mutants E420A and
L417A exhibit dominant negative properties with respect
to transcriptional activation (Jurutka et al. 1997). Such
AF-2 altered receptors are inactive transcripti onally, but
can bind l,25(OH)2D3 ligand and heterodimerize
normally on VDREs, the consequence being competition
with wild-type VDR-RXR heterodimers for VDRE
binding. These data argue that the AF-2 of the primary
VDR partner in an RXR-VDR heterodimer is absolutely
required for the mediation of l,25(OH)2D3-activated
transcription, not only for its intrinsic activation potential,
but also because of its presumed role in stabilizing the
retention of l,25(OH)2D3 ligand in the VDR binding
pocket.
What part, if any, is played by the AF-2 domain(Fig. 7) of the RXR 'silent' partner in the RXR-VDR-
l,25(OH)2D3 signal transduction pathway? To investigate
this phenomenon, AF-2 truncated mutants of RXRa
or RXRß were created and tested for their ability to func¬
tion as dominant negative modulators of l,25(OH)2D3-
stimulated transcription (Blanco et al. 1996). Because
previous data with RXR-RAR control of gene expression
seemed to indicate that the RXR AF-2 was dispensable(Durand et al. 1994), we were surprised to find that AF-2
truncated RXRs were potent dominant negative effectors
of l,25(OH)2D3 action in transfected cells (Blanco et al.
1996). We, therefore, conclude that although the RXR
'silent' partner in VDR signaling apparently is not occu¬
pied by retinoid ligand (see Fig. 6), its AF-2 does play
an active role in transcriptional stimulation. A similar
conclusion has also been reached recently by two other
groups studying RXR-RAR action (Chen et al. 1996,
Schulman et al. 1996), with the use of RAR-specific
ligands precluding ligand binding by the RXR partner.
However, Schulman et al. (1996) have introduced a caveat
to the above theory as they point out that AF-2-truncated
RXRs in heterodimers become strong, constitutive
binders of corepressors like the silencing mediators of
retinoid and thyroid hormone receptors (SMRTs). Thus,
an alternative explanation to an active coactivator-binding
role for RXR AF-2 in heterodimers is that it plays a
more passive role in excluding corepressors. In this latter
scenario, truncation or point mutation (Schulman et al.
1996) of RXR AF-2 generates spurious corepressor bind¬
ing rather than compromising coactivator contact. Only
additional research into coactivator and corepressor associ¬
ations of VDR-RXR heterodimers will resolve this issue.
General mechanism for vitamin D hormone action
on transcription
In order to provide a working hypothesis for l,25(OH)2D3
action at the molecular level, we have developed the
model illustrated in Fig. 8. It is based primarily on data
from our laboratory and others studying 1,25(OH)2D3 and
VDR, and it relies on the assumed similarities between
VDR action and that of TR and RAR. VDR is proposed
to exist in target cell nuclei, perhaps very weakly associ¬
ated with DNA, in a monomeric, inactive conformation
with the C-terminal AF-2 domain extended away from
the hormone binding cavity. Upon liganding with
l,25(OH)2D3, VDR assumes an active conformation,
with the AF-2 pivoted into correct position for both
ligand retention and coactivator contact. In addition, the
hormone facilitates interaction of VDR and RXR
through a stabilized heterodimerization interface. In turn,
1,25(OH)2D3-occupied VDR may itself function as a kind
of allosteric regulator of RXR, perhaps by conveying a
confonnational signal through the juxtapositioned dimer¬
ization domains to induce the AF-2 ofRXR into an active
conformation for coactivator binding. As discussed above(see Fig. 6), the joining of preliganded VDR and un-
liganded RXR apparently renders the RXR partner
unresponsive to binding and either activation or dissocia¬
tion by 9-cis RA. Alternatively, if 9-cis RA encounters
RXR monomer first (Fig. 8), or binds to RXR that is
complexed with VDR in an apoheterodimer (Fig. 6), the
retinoid is able to divert the RXR to generate homo¬
dimers and effectively blunt l,25(OH)2D3-driven
transcription.
In the primary activation pathway pictured in Fig. 8,
the RXR-VDR-l,25(OH)2D3 complex recognizes and
targets the genes to be controlled through high affinity
association with the VDRE in a gene promoter region.
Coactivators that are presumed to bind to VDR and RXR
Figure 8 Model for transcriptional activation by 1,25(OH)2D3 on the promoter of a target gene.
AF-2 s are then postulated to link with TAFs/TBP,
thereby looping out DNA 5' of the TATA box. This series
of events positions VDR such that it can independently
recruit TFIIB to the promoter complex, a process that
initiates the assembly of the RNA polymerase II holo-
enzyme into the preinitiation complex. Precedents exist
for transcription factors independently attracting TFIIB,
such as hepatocyte nuclear factor-4 (Malik & Karathanasis
1996), as well as for a sequential, two-step pathway for
activator-stimulated transcriptional initiation (Struhl 1996,
Stargell & Struhl 1996). Using the latter model as an
analogy, the VDR activator would contact both TBP/
TAFs (via
-
coactivator bridges) and TFIIB in order to
initiate RNA polymerase II holoenzyme assembly. The
order of attachment of these two 'arms' of activation has
not been determined but, at least, in the case of acidic
activators, recruitment to the TATA element precedes
interaction with components of the initiation complex(Stargell & Struhl 1996). It is of interest that the mechan¬
ism of l,25(OH)2D3 action depicted in Fig. 8 is not only
essential for induction of bone remodeling and other
vitamin D functions, but is also self-limiting via 24-OHase
induction. In addition, these actions of l,25(OH),D,
would be blunted under conditions within a cell where
9-cis RA concentrations dominate over those of
l,25(OH)2D3.
The above described molecular mechanism whereby
the vitamin D hormone controls gene expression requires
further experimental evaluation. To advance our under¬
standing of the structure/function relationships in VDR, a
physical characterization of the structure of VDR via
X-ray crystallography will be required. Furthermore, in
order to comprehend the genomic action of vitamin D in
calcium homeostatic and other target cells, it will be
necessary to elucidate the detailed involvement of various
RXR isoforms, specific TAFs and novel coactivators/
corepressors that might influence the regulation of differ¬
ent vitamin D-controlled promoters. This information in
its entirety should assist in determining the potential role
for VDR and l,25(OH)2D3 in the pathophysiology of
osteoporosis and other endocrine-related bone diseases.
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